酒精相关肝病失代偿、脂肪性肝炎且mDF<32患者的长期结局
结果显示5年生存率约50%,基线肝性脑病和随访期间未戒酒是5年生存的预测因素。
要点
- mDF<32的酒精性肝炎患者短期死亡风险低,但5年生存率仅约50%。
- 基线肝性脑病和随访期间未戒酒与5年生存率降低相关。
- 多数死亡(80%)为肝病相关,需重视长期管理和戒酒措施。
核心结论
- 酒精性肝炎且mDF<32患者5年死亡率约50%,基线肝性脑病和未戒酒损害长期预后。
研究设计与样本
- 男性占64%,平均年龄51.5±10.3岁,肝硬化者占84%,MELD中位数14(IQR 11.7-16.1),mDF中位数19(IQR 11.1-24)。
- 采用Cox比例风险生存分析识别与5年生存相关的因素。
主要发现
- 随访期间30%患者保持戒酒。
- 1、6、12、24、60个月生存率分别为96.7±1.6%、90.1±2.7%、80.8±3.6%、69.9±4.3%、50.7±4.9%。
- 死亡病例中80%为肝病相关。
- 多变量分析中,基线肝性脑病和戒酒是5年生存的预测因素。
- 基线无肝性脑病与有肝性脑病者5年生存率分别为60.5±5.8%和29.7±8.0%;戒酒者与非戒酒者分别为74.0±8.0%和40.9±5.8%。
临床怎么用
- 对mDF<32的酒精性肝炎患者应关注长期预后,而非仅短期死亡风险。
- 基线肝性脑病提示长期预后较差,需加强随访管理。
- 随访期间确保戒酒是改善长期生存的重要措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with alcoholic hepatitis and a modified Maddrey's discriminant function (mDF) <32 have a low risk of short-term mortality. However, few data exist concerning long-term outcomes. The aims of this study were to evaluate 5-year survival rates and to identify predictive factors for long-term prognosis in this patient population. METHODS: We studied patients from 2 centers who were admitted for hepatic decompensation (ascites, hepatic encephalopathy, or jaundice) and who had histological findings of steatohepatitis and an mDF <32. Clinical and biological parameters were recorded at the time of liver biopsy and alcohol consumption was recorded during follow-up. We performed Cox proportional hazard survival analysis to identify factors associated with 5-year survival. RESULTS: One hundred and twenty-one patients were included (male: 64%, mean age: 51.5 ± 10.3 years, presence of cirrhosis: 84%). The median model for end-stage liver disease and mDF scores were 14 (IQR 11.7-16.1) and 19 (IQR 11.1-24), respectively. During follow-up, 30% of the patients remained abstinent. Survival rates at 1, 6, 12, 24, and 60 months were 96.7 ± 1.6%, 90.1 ± 2.7%, 80.8 ± 3.6%, 69.9 ± 4.3%, and 50.7 ± 4.9%, respectively. The majority of deaths (80%) were liver related. In multivariable analysis, encephalopathy at baseline and alcohol abstinence were predictive of 5-year survival. The 5-year survival rates of patients without and with encephalopathy at baseline were 60.5 ± 5.8% and 29.7 ± 8.0%, respectively, and the 5-year survival rates of abstinent and non-abstinent patients were 74.0 ± 8.0% and 40.9 ± 5.8%, respectively. CONCLUSIONS: The mortality rate of patients with alcoholic hepatitis and an mDF <32 is around 50% at 5 years. Hepatic encephalopathy at baseline and lack of alcohol abstinence impair long-term prognosis. New treatment strategies, including measures to ensure abstinence, are required. LAY SUMMARY: Patients with alcoholic hepatitis that is of intermediate severity have a low risk of short-term mortality but not much is known regarding long-term outcomes for these patients. This study clearly indicates that patients with intermediate disease characteristics have poor long-term outcomes. The presence of hepatic encephalopathy at the time of diagnosis and the absence of alcohol abstinence during follow-up are factors that predict poor long-term mortality.
引用
- Degré D, Stauber RE, Englebert G, et al. Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function <32. J Hepatol. 2020. PMID: 31954208. doi:10.1016/j.jhep.2019.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。